Vericel Corporation reported a 22% increase in total revenue to $77.5 million for Q2 2026, driven by strong growth in its MACI and Burn Care product lines. The company raised its full-year 2026 revenue guidance to $330-$340 million and announced a $200 million share repurchase program, reflecting confidence in sustained growth. Net income reached $2.2 million with a 73% gross margin, supported by robust free cash flow of $14.3 million. Vericel's continued expansion and financial strength position it well for ongoing growth in advanced therapies for sports medicine and burn care.
Crescent Biopharma announced its second quarter 2026 financial results, highlighting progress in clinical trials for its cancer therapies, including CR-001, a PD-1 x VEGF bispecific antibody, and ADC candidates CR-002 and CR-003. The company is enrol...
Ferrari reported Q2 2026 net revenues of €1.94 billion, up 8% year-on-year, driven by a richer product mix and increased personalization sales. Operating profit rose 10% to €605 million with a margin of 31.2%, while net profit grew 9% to €463 million...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.58% stake in Gamma Communications PLC as of July 29, 2026. The disclosure, made under Rule 8.3 of the Takeover Code, indicates ownership of 1,414,785 ordinary shares. This filing is a ...
Microsoft's Q2 results reveal robust fundamentals, including 18% year-over-year revenue growth and strong 26% unlevered free cash flow margins despite increased capital expenditures. The company's rapidly expanding order backlog, up 84% year-over-yea...
Cycurion secured its largest contract ever, a $54.6 million, 10-year deal with a top-5 global consulting firm to modernize and secure a state government's Health and Human Services System. The contract will generate over $5 million annually starting ...
